Loading...
Loading...
In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating and $3.00 price target on
Dynavax TechnologiesDVAX.
In the report, Jefferies noted, “DVAX had recently provided an update on its Heplisav safety study, HBV-23, the critical trial necessary to address the FDA's complete response letter, and so there was no new update in this earnings release. Financials for the quarter were in line. We continue to expect the HBV-23 trial to support a favorable safety and risk-benefit profile for Heplisav, with data around the end of 2015. We maintain our $3 price target and Buy rating.”
Dynavax Technologies closed on Thursday at $1.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in